Current evidence on immune-driven depression

Current evidence supports immune-driven depression as a clinically relevant MDD subtype. Indicators such as hsCRP, comorbid metabolic or inflammatory conditions and motivational anhedonia may help clinicians recognize at-risk patients. Most intervention trials remain limited by small, heterogeneous samples and nonspecific outcome measures. Advances in biomarker-guided stratification represent important steps toward precision psychiatry, aiming to develop tailored, mechanism-based treatments for MDD.